Open Access

KIF2C promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo

  • Authors:
    • Zhenya Gao
    • Huanxia Jia
    • Fang Yu
    • Hongfang Guo
    • Baoyu Li
  • View Affiliations

  • Published online on: August 2, 2021     https://doi.org/10.3892/etm.2021.10528
  • Article Number: 1094
  • Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies with high mortality and morbidity rates. In recent years, HCC targeted therapy has gained increasing attention. Due to the heterogeneity and high metastasis of HCC, more effective therapeutic targets are needed. Kinesin family member 2C (KIF2C), also known as mitotic centromere‑associated kinesin, is a microtubule‑based motor protein which is involved in a variety of important cellular processes, such as mitosis. The effects of KIF2C on cancer progression and development have been widely studied; however, its potential effects on HCC remains unclear. In the present study, high expression of KIF2C in human HCC tissues was demonstrated using The Cancer Genome Atlas database and immunohistochemistry assays. KIF2C expression was associated with HCC prognosis, including overall survival and disease‑free survival. KIF2C expression was also associated with clinical pathological characteristics including the number of tumor nodes (P=0.015) and tumor size (P=0.009). KIF2C knockdown inhibited the proliferation of HCC cells in vitro, confirmed by MTT and colony formation assays, and suppressed tumor growth in mice which was confirmed by a xenograft mouse model. Together, the results suggested that KIF2C may serve as a promising therapeutic target for the treatment of HCC.
View Figures
View References

Related Articles

Journal Cover

October-2021
Volume 22 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gao Z, Jia H, Yu F, Guo H and Li B: KIF2C promotes the proliferation of hepatocellular carcinoma cells<em> in vitro</em> and <em>in vivo</em>. Exp Ther Med 22: 1094, 2021
APA
Gao, Z., Jia, H., Yu, F., Guo, H., & Li, B. (2021). KIF2C promotes the proliferation of hepatocellular carcinoma cells<em> in vitro</em> and <em>in vivo</em>. Experimental and Therapeutic Medicine, 22, 1094. https://doi.org/10.3892/etm.2021.10528
MLA
Gao, Z., Jia, H., Yu, F., Guo, H., Li, B."KIF2C promotes the proliferation of hepatocellular carcinoma cells<em> in vitro</em> and <em>in vivo</em>". Experimental and Therapeutic Medicine 22.4 (2021): 1094.
Chicago
Gao, Z., Jia, H., Yu, F., Guo, H., Li, B."KIF2C promotes the proliferation of hepatocellular carcinoma cells<em> in vitro</em> and <em>in vivo</em>". Experimental and Therapeutic Medicine 22, no. 4 (2021): 1094. https://doi.org/10.3892/etm.2021.10528